Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 3 | Radiation Oncology

Fig. 3

From: Assessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma

Fig. 3

Representative patient treated with reirradiation and temozolomide (ReRT/TMZ) showing the usefulness of IDH1/2 mutational status evaluation in establishing the RIG diagnosis (Case 9). A T2-weighted magnetic resonance image at the initial presentation showing a hyperintense lesion in the left medial frontal lobe (black arrow). B T1-weighted magnetic resonance image with gadolinium enhancement obtained 17 years after the primary tumor showing a contrast-enhanced lesion just posterior to the primary tumor, which was included within the prior radiation field. C Sanger sequencing analysis of the secondary tumor (glioblastoma) showing the homozygous G nucleotide at codon 515 of the IDH2 gene, indicating the IDH2 gene was wild-type. D Sanger sequencing analysis of the primary tumor (diffuse astrocytoma) showing the heterozygous G and A nucleotides at codon 515 of the IDH2 alleles, indicating the IDH2 gene was mutant. E T1-weighted magnetic resonance images with gadolinium enhancement were obtained 23.0 months after the secondary tumor diagnosis showing a distant recurrence in the cerebellum (white arrow)

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us